Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) Return on Sales (2020 - 2025)

Pliant Therapeutics (PLRX) has disclosed Return on Sales for 6 consecutive years, with 159.92% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales changed N/A to 159.92% in Q4 2025 year-over-year; TTM through Dec 2025 was 57.65%, a N/A change, with the full-year FY2023 number at 102.11%, down 8938.0% from a year prior.
  • Return on Sales was 159.92% for Q4 2025 at Pliant Therapeutics, up from 32.27% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 159.92% in Q4 2025 to a low of 688.48% in Q1 2024.
  • A 5-year average of 48.92% and a median of 16.9% in 2021 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: crashed -66029bps in 2024, then surged 75878bps in 2025.
  • Pliant Therapeutics' Return on Sales stood at 12.27% in 2021, then tumbled by -43bps to 17.6% in 2022, then crashed by -480bps to 102.11% in 2023, then plummeted by -574bps to 688.48% in 2024, then soared by 123bps to 159.92% in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Return on Sales are 159.92% (Q4 2025), 32.27% (Q3 2025), and 53.52% (Q2 2025).